Liver Lipocalin 2 Expression in Severely Obese Women With Non Alcoholic Fatty Liver Disease

Abstract

Background:

Lipocalin 2 (LCN2) has been related to obesity, insulin resistance and metabolic disturbance. However, its relation with non alcoholic fatty liver disease (NAFLD) has hardly been studied.

Methods:

We examined LCN2 circulating levels and its protein and gene expression in liver from women with severe obesity and NAFLD. We analyzed the liver histology of 59 white severely obese women (BMI ≥40 Kg/m²): 15 subjects presented normal liver histology or non-significant liver disease (NL), 18 simple steatosis (SS) and 26 non alcoholic steatohepatitis (NASH). We determined the anthropometric and metabolic features of the women. LCN2 levels were determined by an ELISA and liver mRNA expression by real time RT-PCR. We also studied LCN2 expression in HepG2 liver cells under various inflammatory stimuli.

Results:

Liver LCN2 protein and gene expression were higher in NAFLD than in obese with NL. Liver LCN2 gene expression correlated with SS (r=0.351, p=0.016), and its protein expression correlated with NASH (r=0.705, p=0.003).

LCN2 expression was detected in HepG2 cells after the administration of TNFα, IL6, resistin or adiponectin. LCN2 expression was induced by TNFα, IL6 and resistin.

Conclusions:

Liver LCN2 is related to NAFLD in severely obese women. Up-regulation of LCN2 expression is detected in HepG2 cells after exposure to TNFα, IL6 and resistin. These results suggest that LCN2 expression is induced under liver harmful conditions.

Key words

adipocytokines - liver - obesity

• References

• 1 Ahima RS, Osei SY. Adipokines in obesity. Front Horm Res 2008; 36: 182-197
• 2 Tsochatzis EA, Manolakopoulos S, Papatheodoridis GV et al. Insulin resistance and metabolic syndrome in chronic liver diseases: Old entities with new implications. Scand J Gastroenterol 2009; 44: 6-14
• 3 Bedogni G, Miglioli L, Masutti F et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: The dionysos nutrition and liver study. Hepatology 2007; 42: 44-52
• 4 Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006; 43: S99-S112
• 5 Ekstedt M, Franzén LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873
• 6 Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future. Hepatology 2007; 46: 582-589
• 7 Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009; 36: 4-12
• 8 Tilg H, Moschen A. Update on nonalcoholic fatty liver disease: Genes involved in nonalcoholic fatty liver disease and associated inflammation. Curr Opin Clin Nutr Metab Care 2010; 13: 391-396
• 9 Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-969
• 10 Conde J, Scotece M, Gómez R et al. Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. Biofactors 2011; 37: 413-420
• 11 Auguet T, Quintero Y, Terra T et al. Upregulation of lipocalin 2 in adipose tissues of severely obese women: Positive relationship with proinflammatory cytokines. Obesity 2011; 19: 2295-2300
• 12 Wang Y, Lam KS, Kraegen EW et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007; 53: 34-41
• 13 Zhang J, Wu Y, Zhang Y et al. The role of lipocalin-2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol 2008; 22: 1416-1426
• 14 Milner KL, van der Poorten D, Xu A et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1926-1934
• 15 Santin AD, Zhan F, Bellone S et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. International Journal of Cancer 2004; 112: 14-25
• 16 Hemdahl A, Gabrielsen A, Zhu C et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006; 26: 136-142
• 17 Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238
• 18 Vemula M, Berthiaume F, Jayaraman A et al. Expression profiling analysis of the metabolic and inflammatory changes following burn injury in rats. Physiological Genomics 2004; 18: 87-98
• 19 Flo TH, Smith KD, Sato S et al. Lipocalin-2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004; 432: 917-921
• 20 Roudkenar MH, Kuwahara Y, Baba T et al. Oxidative stress induced lipocalin 2 gene expression: Addressing its expression under the harmful conditions. J Radiat Res 2007; 48: 39-44
• 21 Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474
• 22 Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321
• 23 Berger T, Togawa A, Duncan GS et al. Lipocalin-2-deficient mice exhibit increased sensitivity to escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci USA 2006; 103: 1834-1839
• 24 Yang J, Bielenberg DR, Rodig SJ et al. Lipocalin-2 promotes breast cancer progression. Proc Natl Acad Sci 2009; 106: 3913-3918
• 25 Yan QW, Yang Q, Mody N et al. The adipokine lipocalin-2 is regulated by obesity and promotes insulin resistance. Diabetes 2007; 56: 2533-2540
• 26 Stejskal D, Karpísek M, Humenanska V et al. Lipocalin-2: Development, analytical characterization, and clinical testing of a new ELISA. Horm Metab Res 2008; 40: 381-385
• 27 Kanaka-Gantenbein C, Margeli A, Pervanidou P et al. Retinol-binding protein 4 and lipocalin-2 in childhood and adolescent obesity: When children are not just “small adults”. Clin Chem 2008; 54: 1176-1182
• 28 Stienstra R, Duval C, Müller M et al. PPARs, obesity, and inflammation. PPAR Res 2007; 2007: 95974
• 29 Nagasawa T, Inada Y, Nakano S et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006; 536: 182-191
• 30 Kino T, Rice KC, Chrousos GP. The PPAR-delta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur J Clin Invest 2007; 37: 425-433
• 31 Roudkenar MH, Halabian R, Ghasemipour Z et al. Neutrophil gelatinase-associated lipocalin acts as a protective factor against H2O2 toxicity. Arch Med Res 2008; 39: 560-566
• 32 Roudkenar MH, Halabian R, Roushandeh AM et al. Lipocalin 2 regulation by thermal stresses: Protective role of Lcn2/NGAL against cold and heat stresses. Exp Cell Res 2009; 315: 3140-3151
• 33 Jin D, Guo H, Bu SY et al. Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-γ activation and function in lipid homeostasis and energy expenditure. FASEB J 2011; 25: 754-764
• 34 Lee EK, Kim HJ, Lee KJ et al. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Int J Oncol 2011; 38: 325-333
• 35 Lee S, Lee J, Kim S et al. A dual role of lipocalin 2 in the apoptosis and deramification of activated microglia. J Immunol 2007; 179: 3231-3241